Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07236411Phase 1Active Not Recruiting

Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants

Role: lead

NCT07408869Phase 1Not Yet Recruiting

A Phase 1 Study of Cizutamig in IgE Mediated Diseases

Role: lead

NCT07052032Phase 1Active Not Recruiting

An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis

Role: lead

NCT07215650Phase 1Recruiting

Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

Role: lead

NCT07215663Phase 1Recruiting

Clinical Study of Cizutamig in Systemic Lupus Erythematosus

Role: lead

All 5 trials loaded